Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based anti-Cytomegalovirus (CMV) Vaccine (Triplex?), in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function
Details
Age
Adult
Type of Study
Treatment
Locations
Outpatient CTRC
Principal Investigator
Thomas Campbell, MD
Study ID
Protocol Number: 21-4360
More information available at ClinicalTrials.gov: NCT05099965
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers